SHM02
MISSION® ExpressMag® 96-Well Magnetic Kit
Increases transduction efficiency
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
NACRES:
NA.51
UNSPSC Code:
41106609
Product Name
MISSION® ExpressMag® 96-Well Magnetic Kit, Increases transduction efficiency
product line
MISSION®
shelf life
≥2 yr at ~4 °C
storage temp.
2-8°C
Application
MISSION® ExpressMag® 96-Well Magnetic Kit contains all of the components needed to start enhancing your lentiviral transductions. The kit contains a 100 μL vial of ExpressMag™ Beads, enough for 63 wells of a 96 well plate. These beads bind the lentiviral particles and enable the ExpressMag™ magnetic plate to pull the virus down to the surface of cells thereby significantly increasing transduction efficiency. This product is specifically designed to work with 96-well plates. The kit has been documented to enhance MISSION lentiviral transduction of suspension 293T as well as allowing the transduction of primary human cells such as keratinocytes at MOI as low as 1. See the technical bulletin for other cell lines transduced with the ExpressMag system.
MISSION® ExpressMag® 96-Well Magnetic Kit has been used in hepatitis C virus (HCV) replicon luciferase assay.
Disclaimer
Magnets should be kept away from magnetic storage devices, such as hard disks, ID cards, and credit cards, and from electronic devices and ferromagnetic materials. Persons with cardiac pacemakers should not work with these magnets.
General description
To view protocols from Sigma collaborators for ExpressMag system visit the link below.
www.sigmaaldrich.com/mission-protocols
www.sigmaaldrich.com/mission-protocols
Legal Information
ExpressMag is a registered trademark of Sigma-Aldrich Co. LLC
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
E J Murray et al.
Antimicrobial agents and chemotherapy, 55(9), 4311-4319 (2011-06-29)
The current standard of care for hepatitis C virus (HCV) patients is cotreatment with human alpha interferon (IFN-α) and ribavirin. The host factor USP18 functions to regulate the interferon signaling pathway by acting as an off-switch. In order to understand
Knockdown of USP18 increases alpha 2a interferon signaling and induction of interferon-stimulating genes but does not increase antiviral activity in Huh7 cells
Murray EJ, et al.
Antimicrobial Agents and Chemotherapy, 55(9), 4311-4319 (2011)
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service